Center of Excellence
Leaders in the field sharing authoritative insights and institutional best practices
Did you enjoy reading the Schizophrenia Center of Excellence Compendium? Let us know what you liked best and what you would like to see in future coverage.
In a study incorporating genetic data from more than 125,000 people, researchers have implicated 10 new genes in the development of schizophrenia.
Researcher Christian Hakulinen, PhD, shares details of a study which found that higher amounts of time spent in a low-income environment during childhood were associated with increased risk of schizophrenia after age 15.
Sophia Frangou, MD, PhD, FRCPsych, discusses a study that suggests people with schizophrenia develop the vulnerability to hear “voices” years before the onset of symptoms.
Researcher Michael Birnbaum, MD, discusses a recent study which found significant trends in the Facebook activity of young people in the month before the onset of psychosis.
Brian Kirkpatrick, MD, and Gary Hack, DDS, discuss a recently published study examining palate width in subgroups of people with schizophrenia.
SAN FRANCISCO—Panels of speakers at 2 American Psychiatric Association (APA) Annual Meeting sessions encouraged clinicians to consider prescribing clozapine in patients with treatment-refractory schizophrenia, despite the many challenges which come with using the drug.
BLOG: A recent experience showed me that seeing tardive dyskinesia (TD) can be hard, even for people who have made a commitment to look for it.
Anticipate some significant changes in the treatment of schizophrenia over the next 10 years, from a move toward coordinated specialty care to harnessing the power of social media to help identify symptoms sooner, said John M. Kane, MD.
YOUR QUESTIONS ANSWERED
Is there any rationale for using both deutetrabenazine (Austedo) and valbenazine (Ingrezza) at the same time? Find out from Psych Congress cochair Rakesh Jain, MD, MPH.